Mechanism of immune suppression by allogeneic blood transfusion in patients with gastrointestinal cancer.

同种异体输血对胃肠道肿瘤患者免疫抑制的机制。

基本信息

  • 批准号:
    06671303
  • 负责人:
  • 金额:
    $ 0.26万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
  • 财政年份:
    1994
  • 资助国家:
    日本
  • 起止时间:
    1994 至 1995
  • 项目状态:
    已结题

项目摘要

Whether allogeneic blood transfusion gives rise to adverse effect on survival or postoperational infection in patients who received allogeneic blood as compared with those who did not received is controversial. We studied retrospetively survival rate in patients who underwent radical operation for gastrointestinal cancer : 18 allogeneic blood, 33 autologous blood, and 70 no blood transfusion (66 gastric cancer, 29 colon cancer, and 26 rectal cancer), a total of 121 cancer patients were analyzed. We compared 3-year survival rate of the three patient groups ; 86.3% in autologous transfusion group was comparable with 88.1% of no transfusion group but higher, although not significantly, than 76.6% in allogeneic transfusion group. We also analyzed the change of immunological markers, natural killer cell activities and lymphocyte subsets in 8 patients undergoing radical operation. However, we could not find any significant differences among before nad after operation, and among the groups of allogeneic, autologous, and no transfusion. In conclusion, the effects of blood transfusion on survival and immunological markers of the patients with cancer were not demonstrated. A large-scale multi-center study is warranted.
异体输血是否会对接受异体输血的患者的生存或术后感染产生不利影响,与未接受异体输血的患者相比,存在争议。本文回顾性分析了121例胃肠道肿瘤根治术后患者的生存率:18例异体输血,33例自体输血,70例不输血(胃癌66例,结肠癌29例,直肠癌26例)。我们比较了三个患者组的3年生存率;自体输血组的86.3%与无输血组的88.1%相当,但高于同种异体输血组的76.6%,尽管不显著。同时分析了8例根治性手术患者免疫学指标、自然杀伤细胞活性及淋巴细胞亚群的变化。但在术前与术后,异体输血组、自体输血组和未输血组之间,均未发现任何显著性差异。总之,输血对癌症患者的生存率和免疫学标志物的影响尚未得到证实。需要进行大规模多中心研究。

项目成果

期刊论文数量(22)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
H.Tohyama: "Plasma protein fractions-the present states and medical problems" Medical Perspectives. 3(3). 23-31 (1994)
H.Tohyama:“血浆蛋白组分——现状和医学问题”医学观点。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
前田平生: "自己血輸血とエリスロポエチン療法" Surgery Frontier. 2. 37-41 (1995)
Hirao Maeda:“自体输血和促红细胞生成素治疗”《外科前沿》2. 37-41 (1995)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
前田平生: "エリスロポエチンと自己血輸血" Modern Physician. 14. 255-257 (1994)
Hirao Maeda:“促红细胞生成素和自体输血”《现代医师》14. 255-257 (1994)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
H.Tohyama: "Significances, present situations and prospects of autologous transfusion" Hone-Kansetu-Jintai. 7(7). 741-748 (1994)
H.Tohyama:“自体输血的意义、现状和前景”Hone-Kansetu-Jintai。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
遠山 博: "血漿分画製剤-現状と問題点" Biomedical Perspectives. 3. 23-31 (1994)
Hiroshi Toyama:“血浆衍生物 - 现状和问题”生物医学观点 3. 23-31 (1994)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TOHYAMA Hiroshi其他文献

TOHYAMA Hiroshi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TOHYAMA Hiroshi', 18)}}的其他基金

Experimental research on optical card system in the field of blood transfusion.
光卡系统在输血领域的实验研究
  • 批准号:
    03671113
  • 财政年份:
    1991
  • 资助金额:
    $ 0.26万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)

相似海外基金

Fundamental Research for Intervention of Poor Prognostic Factors and Strengthening of Surgical Care System for Gastrointestinal Cancer in Community Medicine
社区医学中胃肠癌不良预后因素干预和加强外科护理体系的基础研究
  • 批准号:
    23K16289
  • 财政年份:
    2023
  • 资助金额:
    $ 0.26万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Investigation of the oncogenic mechanism of novel oncogene SETDB1 in gastrointestinal cancer
新癌基因SETDB1在胃肠道癌中的致癌机制研究
  • 批准号:
    23K08116
  • 财政年份:
    2023
  • 资助金额:
    $ 0.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Functional analysis of BAP1 in the control of gastrointestinal cancer progression and metastasis.
BAP1在控制胃肠癌进展和转移中的功能分析。
  • 批准号:
    23K08126
  • 财政年份:
    2023
  • 资助金额:
    $ 0.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Functional analysis of inflammation-inducing bacteria derived form oral microflora and immunoreactive T cells in gastrointestinal cancer
胃肠癌中口腔微生物群和免疫反应性 T 细胞衍生的炎症诱导细菌的功能分析
  • 批准号:
    23K08201
  • 财政年份:
    2023
  • 资助金额:
    $ 0.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Multi-site Gastrointestinal Cancer Detection by Stool DNA Methylation
通过粪便 DNA 甲基化进行多部位胃肠癌检测
  • 批准号:
    10443018
  • 财政年份:
    2023
  • 资助金额:
    $ 0.26万
  • 项目类别:
Improving Diagnosis in Gastrointestinal Cancer: Integrating Prediction Models into Routine Clinical Care
改善胃肠癌的诊断:将预测模型纳入常规临床护理
  • 批准号:
    10641060
  • 财政年份:
    2023
  • 资助金额:
    $ 0.26万
  • 项目类别:
Study on fibrotic niche generation for promotion of gastrointestinal cancer metastasis
纤维化微环境生成促进胃肠癌转移的研究
  • 批准号:
    22KF0154
  • 财政年份:
    2023
  • 资助金额:
    $ 0.26万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Development of AI-based hospital stay management support system - Perioperative DPC data exploration for gastrointestinal cancer
基于AI的住院管理支持系统开发——消化道肿瘤围手术期DPC数据探索
  • 批准号:
    22K10407
  • 财政年份:
    2022
  • 资助金额:
    $ 0.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Systematic liquid biopsy to monitor residual disease and treatment efficacy in gastrointestinal cancer patients
系统液体活检监测胃肠道癌症患者的残留病灶和治疗效果
  • 批准号:
    10697368
  • 财政年份:
    2022
  • 资助金额:
    $ 0.26万
  • 项目类别:
Analysis of the mechanism of acquisition of anticancer drug resistance using gastrointestinal cancer organoids
胃肠道肿瘤类器官获得抗癌耐药性的机制分析
  • 批准号:
    22K07013
  • 财政年份:
    2022
  • 资助金额:
    $ 0.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了